
CCP Mounting Unrestricted Warfare to Suppress Shen Yun, Lawmaker Says
The Chinese regime's growing campaign to suppress a New York-based performing arts firm is tantamount to unrestricted warfare, according to Rep. Scott Perry (R-Pa.).
'They fight on every single inch of the battlefield,' Perry told The Epoch Times, referring to the Chinese Communist Party.
Unrestricted warfare is a doctrine that leverages all available nonmilitary means to subdue an enemy. Under such tactics, China is taking advantage of the U.S. judicial system and the freedom of the media, Perry added.
Shen Yun showcases dance and music performances under the tagline 'China before communism.' The company was founded in 2006 by practitioners of Falun Gong—a faith group brutally persecuted by the Chinese regime since 1999—and has been a target of the CCP since.
Over the past year, the regime's effort targeting Shen Yun has escalated significantly, with dozens of
Perry, who sits on the House foreign affairs and intelligence committees, said it was important to take these threats seriously.
Related Stories
5/19/2025
5/6/2025
It's important for the United States and the West in general to 'understand the pathology of this enemy,' he said. 'The CCP just takes advantage of the U.S. judiciary system and also the freedom of the media.'
For the intimidation emails, the senders use Virtual Private Network, or VPN, making it hard to trace where the emails are from, 'but we're well familiar with the threats and the coercion and the intimidation by the Communist Chinese Party,' said Perry.
Taiwan authorities have
Shen Yun emcee Leeshai Lemish speaks at a press conference highlighting the Chinese Communist Party's transnational repression activities targeting the company at the Lincoln Center in New York City on March 26, 2025.
Samira Bouaou/The Epoch Times
'Terrorism'
Shen Yun performances often include stories about human rights abuses that Falun Gong practitioners suffer in China for adhering to their faith, which some performers and their family members
In 1999, the CCP launched a systematic elimination campaign against Falun Gong, which by then had at least 70 million practicing. Since then, millions have been detained inside prisons, labor camps, and other facilities, with hundreds of thousands tortured while incarcerated,
Indiana state Rep. Craig Haggard, who in April proposed a resolution to recognize Shen Yun's artistry and values, recalled how watching Shen Yun led him to learn about forced organ harvesting, which the Chinese regime systematically carries out in China targeting prisoners of conscience, such as Falun Gong practitioners. As a father, it moves him to know that ordinary families in China would be targeted as state enemies, and the authorities could 'just have control over your family's life and death.'
Shen Yun, he said, is trying to showcase 'the beautiful part of China' while highlighting the darkness under communist rule.
Haggard called the bomb threats against Shen Yun 'outrageous' and a form of 'terrorism.'
'They're trying to intimidate through threatened potential violence, and this is going on in our own backyard,' Haggard told The Epoch Times. He added that the Shen Yun artists, while relatively safe within U.S. borders, are 'still taking a huge risk by directly challenging' the regime on its human rights abuses.
The House Armed Services Committee's Oversight and Investigations Subcommittee Chairwoman Vicky Hartzler (R-Mo.) delivers remarks during a hearing in the Rayburn House Office Building on Capitol Hill on Feb. 12, 2015.Keeping the 'Pressure up'
Vicky Hartzler, a commissioner of the U.S. Commission on International Religious Freedom and former congresswoman from Missouri, said the bomb threats also reveal fear from the Chinese authorities.
'It just shows the level of threat that they see from this group, and for how successful these events are in fostering positive relationships between other countries and the Chinese people, and certainly practitioners of Falun Gong,' Hartzler told The Epoch Times.
'The Chinese Communist Party sees this as a threat, and they're escalating the degree of persecution' and 'trying to silence this positive voice.'
The Chinese regime has exploited free speech in the United States to conduct targeted disinformation campaigns, she said, but 'where Chinese authorities may be putting out disinformation, there's certainly an opportunity to set the record straight by putting out the correct information.'
She finds it a reminder to educate average Americans on the tactics the regime uses.
'We need to be vigilant, but also we need to be assertive and shut them down when we can,' she said. 'So we're not so vulnerable to be taken in by them.'
Rep. Chris Smith (R-N.J.), co-chair of the Congressional-Executive Commission on China, listens during a press conference on the Stop Forced Organ Harvesting Act passed by the House on Capitol Hill on May 7, 2025.
Madalina Vasiliu/The Epoch Times
Rep. Chris Smith (R-N.J.), a member of the House Foreign Affairs Committee and co-chair of the Congressional-Executive Commission on China, voiced a similar sentiment.
The United States needs to 'push back even harder,' he said.
Communist China is the 'worst repressive state on the face of the earth,' he told The Epoch Times. 'So we've got to stand up to those who are getting hurt, tortured when they get arrested.'
He said the U.S. government 'will bring more focus on transnational repression' from China and that he hopes President Donald Trump, when he meets with the Chinese regime leader Xi Jinping, will urge the release of incarcerated Americans and people imprisoned for their faith.
'We're going to keep the pressure up.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Newsweek
26 minutes ago
- Newsweek
Poland Election: Ukraine Skeptic Candidate Swings Surprise Victory
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Poland's relationship with Ukraine and the U.S. will become a new focus of the country's politics following the presidential election victory of right-wing nationalist Karol Nawrocki, a Warsaw-based political expert has told Newsweek. Why It Matters Sunday's election was being closely watched as a signifier of Poland's political direction including its approach to Polish-Ukrainian relations. Nawrocki, who was supported by the opposition Law and Justice (PiS) party, is said to adopt a "Trumpian" style of politics and during the campaign he visited the Oval Office where he was pictured with the U.S. president. U.S. Homeland Security Secretary Kristi Noem had urged Poles to elect him. Karol Nawrocki, presidential candidate for the Law and Justice Party, following the Polish presidential runoff election on June 1, 2025, in Warsaw, Poland. Karol Nawrocki, presidential candidate for the Law and Justice Party, following the Polish presidential runoff election on June 1, 2025, in Warsaw, Poland. Sean Gallup//Getty Images What To Know In Sunday's run-off, Nawrocki defeated his liberal rival, Warsaw Mayor Rafal Trzaskowski, according to Poland's National Election Commission, in a surprise turnaround from the first exit poll which indicated that Trzaskowski was ahead. Nawrocki got the support of President Donald Trump and he backs Warsaw's support for Ukraine against Russian aggression, but does not want to see Kyiv join NATO nor the EU. "Poland remains deeply divided," Piotr Buras, senior policy fellow at the European Council on Foreign Relations, told Newsweek on Monday. After all the votes were counted, Poland's electoral commission said Nawrocki had won 50.9 percent of the vote, compared with Trzaskowski's 49.1 percent. It was a switch from an exit poll at 9 p.m. Sunday that showed Trzaskowski ahead 50.3 percent to 49.7 percent, after which he declared a premature victory. Trzaskowski's campaign hinged on supporting Prime Minister Donald Tusk's democratic reforms. While Poland has a parliamentary system in which the president's authority is largely ceremonial, the head of state can veto legislation proposed by lawmakers. The president has a key role in foreign affairs and serves as commander-in-chief of the armed forces and Nawrocki is likely to continue to use his veto power to block Tusk's pro-EU program. The result is also likely also rejuvenate the conservative PiS opposition that lost power eighteen months ago as it eyes taking on Tusk's coalition in 2027 parliamentary elections. Buras, head of the ECFR's Warsaw office, told Newsweek that Warsaw's relations with the U.S. and Ukraine are likely to become subject to party political conflict. Buras said Nawrocki and the PiS will play the Trump or American card in domestic politics, criticizing Tusk's alleged abandoning of the trans-Atlantic partnership by siding with Poland's European allies. Nawrocki has struck an "anti-Ukrainian" sentiment on the campaign trail, reflecting his own convictions as the head of the Institute for National Remembrance which embraces nationalist historical narrative, he said. Both Poland's role as a promoter of a stronger EU defense policy and as an important actor in Ukraine's EU and NATO integration process could be seriously hampered given the changed domestic political context, added Buras. What People Are Saying Piotr Buras, senior policy fellow at the European Council on Foreign Relations: "This election was a battle between two strong negative emotions—or 'projects fear' Between the rejection of the Tusk government and the fear of [a] PiS return to power." What Happens Next Nawrocki will succeed Andrzej Duda, a conservative whose second and final term ends on August 6. Poland's president serves for a five-year period and may be reelected once under the country's constitution. The U.S. has about 10,000 troops in Poland and Homeland Security Secretary Noem suggested military ties could deepen with Nawrocki as president. But Buras said Poland will enter a period of conflict and instability, with a weakened government in terms of legitimacy and ability to act. While a snap election is not likely this year, it could happen as early as 2026, Buras added.
Yahoo
44 minutes ago
- Yahoo
FTSE 100 LIVE: Markets slide as China accuses US of violating trade deal
The FTSE 100 (^FTSE) and European stocks slipped on Monday as China said the US "severely violated" the terms of their recent trade truce. Chinese officials said they would take strong measures to defend the country's interests. The two countries recently agreed to a 90-day moratorium after talks in Geneva, pledging to lower the tariffs on each other's goods. The US lowered its levy on imports from 145% to 30%, while China dropped its import tariff from 125% to 10%. China said the US had "seriously undermined" the agreement. The comments come after US president Donald Trump said on Friday that China had "totally violated its agreement with us". Beijing said violations included the US blocking sales of computer chip design software to Chinese companies and warning against the use of Chinese computer chips made by companies such as Huawei. They also said the US had cancelled visas for Chinese students. London's premier index fell 0.3%, having opened higher. Defence contractor Babcock International (BAB.L) rose the most, as the UK announced plans to build up a fleet of 12 attack submarines. Germany's DAX (^GDAXI) fell slightly, while the CAC 40 (^FCHI) was 0.2% lower. The pan-European STOXX 600 (^STOXX) was down 0.1%. Last week, Europe agreed its own stay of execution in trade negotiations with the US, pushing back the implementation of a 50% import tariff to July while talks continue on a possible deal. Drug maker Indivior has announced plans to delist its shares from the London Stock Exchange (LSE), marking the latest company to abandon the UK market for the US. However, the LSE welcomes Anglo-American's platinum spin-off Valterra after becoming independent from the mining giant. Indivior's exit comes after the company moved its primary listing to the US's Nasdaq index last year. It said cancelling the secondary listing in London eliminates 'cost and complexity' and better reflects the business – with more than 80% of its revenues generated in the US. It also said liquidity on the Nasdaq now 'far outweighs' that of the LSE with a greater level of trading. The US-based pharmaceutical firm makes prescription medicines to treat opioid addiction, and has a market capitalisation of £1.2bn. 'A single primary listing on Nasdaq best reflects the profile of Indivior's business,' chairman David Wheadon said. Here's Pedro Goncalves full take on UK house prices: Views from the market: Jonathan Hopper, CEO of Garrington Property Finders, said: CEO of Yopa, Verona Frankish, said: Tony Redondo, founder at Cosmos Currency Exchange said: House price growth edged up in May, according to Nationwide. Here are the headlines from their report: Annual rate of house price growth increased marginally in May to 3.5%, compared to 3.4% in April House prices were up 0.5% month on month House prices in predominantly rural areas have risen by 23% over the last five years, compared to 18% in more urban areas The average price in May was £273,427, compared with £270,752 in April. Robert Gardner, Nationwide's chief economist, said: Asian stocks traded lower on Monday as trade tensions, again, escalate between the US and China. US stock futures edged lower Monday morning, as investors turned the page on a bullish May and eyed the month ahead with trade uncertainty lingering. S&P 500 futures (ES=F) were down 0.4%, as futures tied to the Dow Jones Industrial Average (YM=F) sank 0.5%. Contracts tied to the Nasdaq 100 (NQ=F) slipped 0.6%. The tepid start to June follows a standout May: The S&P 500 (^GSPC) rallied more than 6% in its best month since November 2023 and best May since 1990. The Nasdaq Composite (^IXIC) soared 9%, and the Dow (^DJI) notched a 4% gain. Tech stocks led the charge, as investor optimism around AI and resilient economic data fuelled risk appetite. Read more on Yahoo Finance Hello from London. Lucy Harley-McKeown here, ready to bring you the markets and business news of the day. We have a few diary items to start us off: PMI releases for the EU, UK and US Nationwide's house price index The monthly money and credit report from the Bank of England In the US, corporate results from Campbell Soup (CPB). Let's get to it. Drug maker Indivior has announced plans to delist its shares from the London Stock Exchange (LSE), marking the latest company to abandon the UK market for the US. However, the LSE welcomes Anglo-American's platinum spin-off Valterra after becoming independent from the mining giant. Indivior's exit comes after the company moved its primary listing to the US's Nasdaq index last year. It said cancelling the secondary listing in London eliminates 'cost and complexity' and better reflects the business – with more than 80% of its revenues generated in the US. It also said liquidity on the Nasdaq now 'far outweighs' that of the LSE with a greater level of trading. The US-based pharmaceutical firm makes prescription medicines to treat opioid addiction, and has a market capitalisation of £1.2bn. 'A single primary listing on Nasdaq best reflects the profile of Indivior's business,' chairman David Wheadon said. Here's Pedro Goncalves full take on UK house prices: Views from the market: Jonathan Hopper, CEO of Garrington Property Finders, said: CEO of Yopa, Verona Frankish, said: Tony Redondo, founder at Cosmos Currency Exchange said: House price growth edged up in May, according to Nationwide. Here are the headlines from their report: Annual rate of house price growth increased marginally in May to 3.5%, compared to 3.4% in April House prices were up 0.5% month on month House prices in predominantly rural areas have risen by 23% over the last five years, compared to 18% in more urban areas The average price in May was £273,427, compared with £270,752 in April. Robert Gardner, Nationwide's chief economist, said: Asian stocks traded lower on Monday as trade tensions, again, escalate between the US and China. US stock futures edged lower Monday morning, as investors turned the page on a bullish May and eyed the month ahead with trade uncertainty lingering. S&P 500 futures (ES=F) were down 0.4%, as futures tied to the Dow Jones Industrial Average (YM=F) sank 0.5%. Contracts tied to the Nasdaq 100 (NQ=F) slipped 0.6%. The tepid start to June follows a standout May: The S&P 500 (^GSPC) rallied more than 6% in its best month since November 2023 and best May since 1990. The Nasdaq Composite (^IXIC) soared 9%, and the Dow (^DJI) notched a 4% gain. Tech stocks led the charge, as investor optimism around AI and resilient economic data fuelled risk appetite. Read more on Yahoo Finance Hello from London. Lucy Harley-McKeown here, ready to bring you the markets and business news of the day. We have a few diary items to start us off: PMI releases for the EU, UK and US Nationwide's house price index The monthly money and credit report from the Bank of England In the US, corporate results from Campbell Soup (CPB). Let's get to it. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
an hour ago
- Medscape
Chronotherapy in RA Treatment: Tantalizing but Under-Studied
Morning stiffness is common for people with arthritis and that got researchers to thinking that if they could time drug therapy to match the body's rhythms when pain receptors are most active, they could relieve that morning stiffness and potentially target flares. That concept, known as chronotherapy or chronomedicine, aims to synchronize drug delivery to the body's circadian rhythms. A few small clinical trials and observational studies have evaluated this concept, but most recently researchers in Japan completed a multicenter, nonrandomized, controlled study that found that almost twice as many patients who took baricitinib at night had a measurable improvement in symptoms than patients who took the Janus kinase (JAK) inhibitor in the morning. Amanda Sammut, MD 'Chronotherapy refers to the strategic timing of medication, therapies, or other medical interventions to align with the body's natural circadian rhythms,' Amanda Sammut, MD, chief of rheumatology at Harlem Hospital Center in New York City, told Medscape Medical News. 'The goal of chronotherapy is to optimize therapeutic efficacy and minimize adverse events.' Progress Slows After Nobel Prize In 2017, Jeffrey Hall, Michael Rosbash, and Michael Young won the Nobel Prize in Medicine for their work isolating a gene that controls the normal daily biological rhythms. However, as researchers in Italy who have studied chronotherapy in inflammatory joint diseases have noted, transition of that knowledge to clinical practice has proceeded slowly. 'Growing knowledge of chronobiology applied to inflammatory joint diseases could stimulate the development of new drug strategies to treat patients in accordance with biological rhythms and minimize side effects,' the Italian researchers wrote. 'It should be evidence-based,' John Hogenesch, PhD, a neuroscientist at Cincinnati Children's Hospital, Cincinnati, who has researched circadian rhythms, told Medscape Medical News. 'Yet there are only about 140 studies in 50 years looking at drug timing.' Sammut noted that chronotherapy is not yet incorporated into major rheumatoid arthritis (RA) treatment guidelines. 'The temporal administration of anti-inflammatory agents to coincide with this cytokine surge presents a theoretically sound strategy to improve disease activity,' she said. Akira Hashiramoto, MD, PhD The most recent research in Japan, led by Akira Hashiramoto, MD, PhD, at Kobe University, Kobe, Japan, assigned 122 patients with RA to four open-label treatment groups: Either baricitinib 2 mg or 4 mg in the morning or evening. The primary endpoint was the percentage of patients with at least 20% improvement in the American College of Rheumatology response criteria (ACR20) at 12 weeks. Some of the secondary endpoints included ACR20, ACR50, and ACR70 response rates at other timepoints as well as changes in the Clinical Disease Activity Index (CDAI) at the same timepoints out to 1 year. Hashiramoto told Medscape Medical News that the changes in swollen joint count (SJC) significantly improved in the evening vs the morning dosing group throughout the 52-week study period, and that changes in tender joint count, patient global assessment, and physician global assessment mostly occurred before 3 months. 'Therefore, we believe that the most important mechanism for achieving sustained CDAI remission at weeks 12, 24, and 52 is that chronotherapy maximized the effect of baricitinib by week 12 after initiation, when all components of CDAI have responded well,' he said. 'The results demonstrate the crucial importance of the treat-to-target strategy.' Earlier studies demonstrated the potential of chronotherapy. Researchers in Berlin, led by Frank Buttgereit, MD, at Charité-Universitätsmedizin Berlin, Berlin, Germany, reported in 2008 that modified-release prednisone reduced the duration of morning stiffness in RA. In 2013, Buttgereit's group reported that low-dose prednisone chronotherapy when added to existing disease-modifying antirheumatic drugs produced significantly higher response rates than placebo for ACR20 — 48% vs 29% ( P < .001), and more than double the rate for a 50% improvement (22% vs 10%, P < .006). A 2011 study in Japan found that methotrexate chronotherapy can improve RA symptoms compared with traditional dosing methods, but Sammut cautioned that the results may not be entirely related to chronotherapy. The study switched patients from the standard methotrexate dose three times daily to once daily at bedtime, but with the same weekly dosing. 'So even though the results showed improved disease activity scores and functional capacity, it may not be related to the actual chronotherapy portion alone,' Sammut said. Role of the Circadian Clock The body's circadian clock is central to chronotherapy. A few studies have explored the role of the body's internal clock in RA pathophysiology, including one by Buttgereit's group in Berlin. Buttgereit's group reported in 2015 that circadian disruption altered circulating leukocyte rhythms in patients with RA. Specifically, they found the rhythms of effector CD8 + and CD4+ T cells, and interleukin (IL)–6R+ CD8+ T cells were abolished in patients with RA; and that IL-8R+ monocytes, CD20+ CD27+ memory B cells, and CD20+ human leukocyte antigen –DR+ activated B cells, which were not rhythmic in healthy individuals, had rhythmic circulation in the peripheral blood of patients with RA. Researchers at Nova Southeastern University in Davie, Florida, conducted a literature review in 2023 in which they identified four common clock genes that were dysregulated in patients with RA: Circadian locomotor output cycles kaput; brain and muscle ARNT like-1 ; period ; and cryptochrome. Research has also been conducted on the diurnal variation of symptoms of polymyalgia rheumatica. In a 2016 observational study, Danish researchers reported that plasma concentrations of IL-6, IL-8, tumor necrosis factor–α, IL-1β, and IL-4 varied with time in both patients treated with prednisolone and untreated patients, peaking between 4:00 AM and 8:00 AM. With the exception of IL-1β, concentrations of these cytokines and of IL-10 were higher throughout the 24-hour observation period in treated patients, as were melatonin and cortisol levels, the latter peaking around 2:00 AM and 8:00 AM, respectively. Farshid Guilak, PhD In his laboratory at Shriners Hospitals for Children — St. Louis — Farshid Guilak, PhD, has been researching circadian rhythms and timed-release therapy to minimize arthritic flares and prevent disease progression in people with RA or juvenile idiopathic arthritis. 'It turns out that not only does our brain have this region that cycles but virtually every other tissue in the body is on a 24-hour clock,' Guilak told Medscape Medical News. 'Unlike the master clock, they're called the peripheral clocks.' These peripheral clocks in the joints dictate the ebb and flow of pain within them, he said. 'The exact reason is not completely known, but my belief is that our tissues also have periods of activity and rest,' Guilak said. 'During the night we elevate a lot of the proteins and genes that are related to repair and regeneration, things that are related to cleaning out the cells, such as the process of autophagy. It's very important in the brain and memory that if you don't have these sleep periods, you don't actually allow your tissues to reset and repair themselves.' Inflammatory mediators peak between 3:00 AM and 5:00 AM, he said. 'This is one reason why many people with arthritis wake up with morning stiffness,' he said. 'The clock regulates about 50% of drug transporters, targets, and metabolizing enzymes,' Hogenesch said. 'About half of all small-molecule drugs have a short (less than 12-hour) half-life. This means as many as 25% of all drugs may be influenced by when they are taken.' Guilak's group reported that people who work night shift had a 25% higher risk for knee osteoarthritis and a 30% higher risk of having knee replacement than nonshift workers. 'Disruption of sleep is a major risk factor for arthritis,' he said. 'Doing shift work or getting < 6 hours of sleep a night significantly increases the risk of osteoarthritis.' Challenges in Adapting Chronotherapy in RA Chronotherapy faces several barriers before it gains wider acceptance as a treatment approach in RA. One involves identifying specific circadian patterns in individual patients. 'The gold standard is the dim-light melatonin onset assay, which is only done in a tiny subset of patients in a tiny subset of academic medical centers,' Hogenesch said. More practical methods, he said, are using surveys, such as the Munich ChronoType Questionnaire, or actigraphy, which uses wearables, such as a Fitbit or Oura ring. 'So [it will be] surveys and wearables for the near future,' he said. The complexity of medical regimens for patients with RA poses another barrier to wider acceptance, Summat said. 'The medication regimen for patients with RA, and for many other chronic diseases, usually includes multiple medications,' she said. 'When you include timings of medications, it may make it more complicated and more difficult to adhere to the regimen.' But other patients may be amenable to having a medication schedule, Sammut said. 'Timing of medications is something that we should think about in our patients already,' she said. 'For instance, if a patient is on a proton pump inhibitor, we would recommend taking it on an empty stomach half an hour before eating or drinking anything.' She suggested that physicians and pharmacists should collaborate on developing medication plans for patients. Individual patients' sleep schedules are another factor to consider with chronotherapy, Sammut added. Chronotherapy With Other Drugs The JAK inhibitors tofacitinib and upadacitinib could potentially be used for chronotherapy in RA, Hashiramoto said. 'The half-life, time after administration of the drug to reach maximum plasma concentration, or drug withdrawal of tofacitinib and upadacitinib are different from that of baricitinib, so the efficacy of bedtime dosing must be demonstrated in clinical trials,' he said. 'However, in our limited experience, tofacitinib tends to respond well in patients who start with only a single evening dose, with similar results to baricitinib 2 mg in the evening,' he said. 'For upadacitinib, once daily in the evening is as effective as baricitinib.' Based on his group's research, Hashiramoto said that chronotherapy does not increase adverse events with either tofacitinib or upadacitinib. 'We hope that follow-up studies of chronotherapy will be conducted in Europe and the United States, not only for baricitinib, but also for other JAK inhibitors,' he said. Emerging Research: Unlocking Gene Circuits Guilak's research group has been investigating 'chronogenetics,' circadian-based gene circuits that can be programmed into stem cells and that, once implanted in the body, match the patient's circadian clock to deliver anti-inflammatory drugs daily at a specific time. The stem cells are administered in a drug-eluting implant — 'like a spaghetti string rod full of cells injected under the skin,' he said — that is inserted into the joint. It's designed to release drugs once a day. Guilak reported that these gene circuits produced effective amounts of IL-1 receptor antagonist in mice. More recently, Guilak's group reported on an implant that responds to both circadian and inflammatory signals to release therapeutic levels of IL-1 receptor antagonist not only at a specific time but also in response to activation of pain receptors. His group recently received a grant from the Advanced Research Project Agency for Health to develop the implant. 'Our goal is to get this into patients in the next 3-5 years,' he said. Hashiramoto reported receiving honoraria from AbbVie and honoraria and grants from Eli Lilly Japan. Guilak is an employee and shareholder of Cytex Therapeutics and has applied for patents on concepts on chronogenetics. Sammut and Hogenesch reported no relevant financial relationships.